Searchable abstracts of presentations at key conferences in endocrinology
ISSN 1470-3947 (print)
| ISSN 1479-6848 (online)
Endocrine Abstracts
Menu
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Search
Issues/Conferences
Cite
About
Our Services
Policies
Contact
Disclaimer
Previous issue
|
Volume 47
|
Theranostics2016
|
Next issue
4th Theranostics World Congress
All volumes
0105 UKINETS2024
0104 SFEIES24
0103 BSPED2024
0102 EYES2024
0101 ETA2024
0100 SFEEU2024
0099 ECE2024
0098 NANETS2023
0097 BES2023
0096 UKINETS2023
0095 BSPED2023
0094 SFEBES2023
0093 EYES2023
0092 ETA2023
0091 SFEEU2023
0090 ECE2023
0089 NANETS2022
0088 BES2022
0087 UKINETS2022
0086 SFEBES2022
0085 BSPED2022
0084 ETA2022
0083 EYES2022
0082 SFEEU2022
0081 ECE2022
0080 UKINETS2021
0079 BES2021
0078 BSPED2021
0077 SFEBES2021
0076 CHD2021
0075 EYES2021
0074 SFENCC2021
0073 ECE2021
0072 UKINETS2020
0071 BES2020
0070 ECE2020
0069 SFENCC2020
0068 UKINETS2019
0067 EYES2019
0066 BSPED2019
0065 SFEBES2019
0064 BES2019
0063 ECE2019
0062 EU2019
0061 OU2019
0060 UKINETS2018
0059 SFEBES2018
0058 BSPED2018
0057 BES2018
0056 ECE2018
0055 SFEEU2018
0054 NuclearReceptors2018
0053 OU2018
0052 UKINETS2017
0051 BSPED2017
0050 SFEBES2017
0049 ECE2017
0048 SFEEU2017
0047 Theranostics2016
0046 UKINETS2016
0045 BSPED2016
0044 SFEBES2016
0043 WCTD2016
0042 Androgens2016
0041 ECE2016
0040 ESEBEC2016
0039 BSPED2015
0038 SFEBES2015
0037 ECE2015
0036 BSPED2014
0035 ECE2014
0034 SFEBES2014
0033 BSPED2013
0032 ECE2013
0031 SFEBES2013
0030 BSPED2012
0029 ICEECE2012
0028 SFEBES2012
0027 BSPED2011
0026 ECE2011
0025 SFEBES2011
0024 BSPED2010
0023 BSPED2009
0022 ECE2010
0021 SFEBES2009
0020 ECE2009
0019 SFEBES2009
0018 MES2008
0017 BSPED2008
0016 ECE2008
0015 SFEBES2008
0014 ECE2007
0013 SFEBES2007
0012 SFE2006
0011 ECE2006
0010 SFE2005
0009 BES2005
0008 SFE2004
0007 BES2004
0006 SFE2003
0005 BES2003
0004 SFE2002
0003 BES2002
0002 SFE2001
Summary
Abstract Book
Volume Editors
Abstracts
Contents
4th Theranostics World Congress 2016
Oral Speaker Communications
Spotlight on Neuroendocrine tumours
Integrating cancer genomics with imaging
ea0047oc1
Production of Ga-68 radiotracers under GMP and regulatory aspects - a German perspective
ea0047oc2
Optimised production of 64Cu-SARTATE for a phase 1 clinical trial
ea0047oc3
68Ga, 64Cu labelling and affinity study of NODAGANOC, a NODAGA conjugated somatostatin analogue
ea0047oc4
Influence of the radiopharmaceutical affinity and peptide content on the pharmacokinetics: [68Ga]Ga-DOTATOC and [68Ga]Ga-DOTATATE
ea0047oc5
DNA damage assay in blood lymphocytes in peptide receptor radionuclide therapy patients with personalised high activities
ea0047oc6
Two Decades of THERANOSTICS in Neuroendocrine Tumors - Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT)
ea0047oc7
NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis
ea0047oc8
Clinical Perspective: The 'difficult development situation': how to approach and overcome challenges from a regulatory perspective
ea0047oc9
The Cruel Wait for PRRT
ea0047oc10
The challenges of waiting for RCTs vs treating patient's now
ea0047oc11
PET/CT based dosimetry for 90Y-DOTATOC treatment of neuroendocrine cancer
ea0047oc12
Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumors: a simulation study
ea0047oc13
68Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a head-to-head comparison with DOTATOC and FDG PET/CT
ea0047oc14
Evaluation of somatostatin, CXCR4 chemokine and endothelin a receptor expression in a large series of paragangliomas
ea0047oc15
Benefits and challenges of translating pre-clinical studies into clinical practice
ea0047oc16
Dosimetry in 177Lu treatment: what we know and what we do not know
ea0047oc17
Spotlight on Prostate Cancer
The Holy Grail: individualised dosimetry for radionuclide therapy
ea0047oc18
The history of PSMA and future directions
ea0047oc19
Evolving evidence of PSMA PET/CT
ea0047oc20
Should PSMA PET/CT replace conventional imaging?
ea0047oc21
PET/MRI: better AND worse than PET/CT for PSMA PET imaging
ea0047oc22
Imaging the expression of gastrin releasing peptide receptors in prostate cancer using Ga-68 labeled antagonists
ea0047oc23
How to get away with PET+MRI
ea0047oc24
Re-assessing gallium-67 as a therapeutic radionuclide
ea0047oc25
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment
ea0047oc26
Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks
ea0047oc27
Theranostic in early detection of recurring prostate cancer: 64CuCl2
ea0047oc28
A short history of transforming the diagnostic tracer PSMA-11 into the theranostic variant PSMA-617
ea0047oc29
Beyond wizardry: creating high level evidence for PSMA PET Imaging and Theranostics
ea0047oc30
First in-man study of 68Ga-THP-PSMA PET in patients with primary prostate cancer: initial results
ea0047oc31
Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T
ea0047oc32
Molecular imaging with 64Cu-PSMA PET/CT in Theranostics of prostate cancer
ea0047oc33
Radiolabelling of DOTAMZOL with 68Ga and 44Sc for clinical application
ea0047oc34
Innovative Theranostics
Kit-based Ga-68 PET imaging
ea0047oc35
Bone seeking bisphosphonate therapy
ea0047oc36
The development of copper-based imaging and therapeutics agents
ea0047oc37
How I do it; delivering outpatient theranostics
ea0047oc38
The success and failure of radioimmunotherapy for lymphoma
ea0047oc39
PSMA in breast cancer
ea0047oc40
Theranostics for the invasive cancer phenotype: uPAR targeted theranostics
ea0047oc41
Optimizing theranostics through pretargeting approaches
ea0047oc42
Initial South African experience on 68Ga/213Bi radiolabeling for prospective theranostics
ea0047oc43
Critical aspects of radiochemical purity determination of 68Ga-BCA-peptides and behavioral features of different 68Ga species
ea0047oc44
Glioma tumors grade II/III - local alpha emiters targeted therapy with 213Bi-DOTA-substance P
ea0047oc45
Spatially informed dose deposition of Auger electron-emitting radionuclides at a cell nucleus scale
ea0047oc46
Noninvasive imaging of multiple Myeloma with 68Ga-DOTA-PEG4-LLP2A via targeting VLA-4
ea0047oc47
Theranostics at its best: clinical breast cancer imaging and quantification targeting HER2 receptors
ea0047oc48
Production of 68Ga in a mid-energy cyclotron: the solution is in the target
ea0047oc49
Radiolabel results from high specific activity e-LINAC produced 67Cu
ea0047oc50
Ga-68 research status in Asia
ea0047oc51